Zai Lab Ltd
0 products tracked · names used in filings: Zai Lab Ltd
Upcoming milestones
Povetacicept: PDUFA target action date (immunoglobulin A nephropathy (IgAN) in adults, accelerated approval)
Zai Lab Ltd (ZLAB); povetacicept; BLA; status: set; "…Povetacicept (pove, APRIL/BAFF): In June 2026, Zai Lab partner Vertex announced that the FDA accepted its BLA submission for pove for accelerated approval in adults with immunoglobulin A nephropathy (IgAN), with a PDUFA target action date of November 30, 2026."; filed 2026-08-06 · source
Recent milestones
Zai Lab Ltd: PDUFA target action date
Zai Lab Ltd (ZLAB); "Seronegative generalized myasthenia gravis (sn-gMG): In January 2026, the FDA accepted for Priority Review a supplemental Biologics License Application (sBLA) for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) sn-gMG, with a Prescription Drug User Fee Act (PDUFA) target action date of May…"; filed 2026-02-26 · source
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.